Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
äŒæ¥ã³ãŒãAYTU
äŒç€ŸåAytu Biopharma Inc
äžå Žæ¥Oct 20, 2017
æé«çµå¶è²¬ä»»è
ãCEOãDisbrow (Joshua R)
åŸæ¥å¡æ°82
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Oct 20
æ¬ç€Ÿæåšå°7900 E. Union Avenue
éœåžDENVER
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·80237
é»è©±çªå·17204376580
ãŠã§ããµã€ãhttps://aytubio.com/
äŒæ¥ã³ãŒãAYTU
äžå Žæ¥Oct 20, 2017
æé«çµå¶è²¬ä»»è
ãCEOãDisbrow (Joshua R)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã